These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 11509996)

  • 1. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.
    Lee MS; Greenberg DP; Yeh SH; Yogev R; Reisinger KS; Ward JI; Blatter MM; Cho I; Holmes SJ; Cordova JM; August MJ; Chen W; Mehta HB; Coelingh KL; Mendelman PM
    J Infect Dis; 2001 Oct; 184(7):909-13. PubMed ID: 11509996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy.
    Greenberg DP; Walker RE; Lee MS; Reisinger KS; Ward JI; Yogev R; Blatter MM; Yeh SH; Karron RA; Sangli C; Eubank L; Coelingh KL; Cordova JM; August MJ; Mehta HB; Chen W; Mendelman PM
    J Infect Dis; 2005 Apr; 191(7):1116-22. PubMed ID: 15747247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.
    Belshe RB; Newman FK; Tsai TF; Karron RA; Reisinger K; Roberton D; Marshall H; Schwartz R; King J; Henderson FW; Rodriguez W; Severs JM; Wright PF; Keyserling H; Weinberg GA; Bromberg K; Loh R; Sly P; McIntyre P; Ziegler JB; Hackell J; Deatly A; Georgiu A; Paschalis M; Wu SL; Tatem JM; Murphy B; Anderson E
    J Infect Dis; 2004 Feb; 189(3):462-70. PubMed ID: 14745704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.
    Karron RA; Belshe RB; Wright PF; Thumar B; Burns B; Newman F; Cannon JC; Thompson J; Tsai T; Paschalis M; Wu SL; Mitcho Y; Hackell J; Murphy BR; Tatem JM
    Pediatr Infect Dis J; 2003 May; 22(5):394-405. PubMed ID: 12792378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Half-life of human parainfluenza virus type 3 (hPIV3) maternal antibody and cumulative proportion of hPIV3 infection in young infants.
    Lee MS; Mendelman PM; Sangli C; Cho I; Mathie SL; August MJ
    J Infect Dis; 2001 Apr; 183(8):1281-4. PubMed ID: 11262213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
    Durbin AP; Cho CJ; Elkins WR; Wyatt LS; Moss B; Murphy BR
    J Infect Dis; 1999 Jun; 179(6):1345-51. PubMed ID: 10228053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers.
    Madhi SA; Cutland C; Zhu Y; Hackell JG; Newman F; Blackburn N; Murphy BR; Belshe RB; Karron RA; Deatly AM; Gruber WC; Bernstein DI; Wright PF
    Vaccine; 2006 Mar; 24(13):2432-9. PubMed ID: 16406170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of vaccines for parainfluenza virus infections.
    Sato M; Wright PF
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S123-5. PubMed ID: 18820572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
    Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
    Belshe RB; Newman FK; Anderson EL; Wright PF; Karron RA; Tollefson S; Henderson FW; Meissner HC; Madhi S; Roberton D; Marshall H; Loh R; Sly P; Murphy B; Tatem JM; Randolph V; Hackell J; Gruber W; Tsai TF
    J Infect Dis; 2004 Dec; 190(12):2096-103. PubMed ID: 15551207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys.
    Skiadopoulos MH; Surman SR; Riggs JM; Collins PL; Murphy BR
    J Virol; 2001 Nov; 75(21):10498-504. PubMed ID: 11581420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.
    Englund JA; Karron RA; Cunningham CK; Larussa P; Melvin A; Yogev R; Handelsman E; Siberry GK; Thumar B; Schappell E; Bull CV; Chu HY; Schaap-Nutt A; Buchholz U; Collins PL; Schmidt AC;
    Vaccine; 2013 Nov; 31(48):5706-12. PubMed ID: 24103895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.
    Bernstein DI; Malkin E; Abughali N; Falloon J; Yi T; Dubovsky F;
    Pediatr Infect Dis J; 2012 Feb; 31(2):109-14. PubMed ID: 21926667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector.
    Haller AA; Miller T; Mitiku M; Coelingh K
    J Virol; 2000 Dec; 74(24):11626-35. PubMed ID: 11090161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys.
    Durbin AP; Wyatt LS; Siew J; Moss B; Murphy BR
    Vaccine; 1998 Aug; 16(13):1324-30. PubMed ID: 9682397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody response of cattle experimentally inoculated with parainfluenza type-3 live vaccine in a post-tracheal position.
    Kadoi K; Watanabe N; Sasagawa T; Kozasa M
    New Microbiol; 1998 Jul; 21(3):249-54. PubMed ID: 9699204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of antibodies and anamnestic response in calves vaccinated with inactivated infectious bovine rhinotracheitis virus and parainfluenza-3 virus vaccines.
    Sweat RL
    J Am Vet Med Assoc; 1983 Apr; 182(8):809-11. PubMed ID: 6303996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.
    Karron RA; Thumar B; Schappell E; Surman S; Murphy BR; Collins PL; Schmidt AC
    Vaccine; 2012 Jun; 30(26):3975-81. PubMed ID: 22178099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.
    Mason JN; Elbahesh H; Russell CJ
    J Virol; 2013 May; 87(10):5959-69. PubMed ID: 23514887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.